Market Place
Sourcing Support
Rezolute Reports 1st Quarter Fiscal 2025 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
Rezolute to Participate in Upcoming Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Rezolute Reports Fourth Quarter And Full Year 2024 Results
19 Sep 2024 //
GLOBENEWSWIRE
US FDA lifts partial clinical hold on Rezolute`s low blood sugar treatment
10 Sep 2024 //
REUTERS
FDA Lifts Partial Clinical Holds On RZ358
09 Sep 2024 //
GLOBENEWSWIRE
Rezolute to Participate in Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Rezolute`s IND For RZ358 Phase 3 Study Cleared By FDA
05 Aug 2024 //
GLOBENEWSWIRE
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
31 Jul 2024 //
GLOBENEWSWIRE
Rezolute Announces Exercise of Underwriters’ Option to Purchase Addi Shares
27 Jun 2024 //
GLOBENEWSWIRE
Rezolute Announces Proposed Public Offering of Stock and Pre-Funded Warrants
13 Jun 2024 //
GLOBENEWSWIRE
Rezolute Prices $60M Public Offering Of Common Stock, Pre-Funded Warrants
13 Jun 2024 //
GLOBENEWSWIRE
Rezolute to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
22 May 2024 //
FIERCE BIOTECH
Rezolute Reports Positive Topline Phase 2 RZ402 Data In DME
21 May 2024 //
GLOBENEWSWIRE
Rezolute Reports Q3 Fiscal 2024 Results, Business Update
15 May 2024 //
GLOBENEWSWIRE
RIZE Study Sub-Analyses at Pediatric Endocrine Society Meeting
23 Apr 2024 //
GLOBENEWSWIRE
Rezolute Reports Validation of the Potential Use of RZ358
06 Mar 2024 //
GLOBENEWSWIRE
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
13 Feb 2024 //
GLOBENEWSWIRE
Rezolute Expands Leadership Team with Appointment of Daron Evans as CFO
24 Jan 2024 //
GLOBENEWSWIRE
Rezolute Receives Innovation Passport Designation from the U.K. Licensing
23 Jan 2024 //
GLOBENEWSWIRE
Rezolute Initiates Phase 3 Study for RZ358 in Congenital Hyperinsulinism
14 Dec 2023 //
GLOBENEWSWIRE
Rezolute Completes Enrollment of Phase 2 Study in Diabetic Macular Edema (DME)
13 Dec 2023 //
GLOBENEWSWIRE
Rezolute to Participate in BTIG™s 3rd Annual Ophthalmology Day
17 Nov 2023 //
GLOBENEWSWIRE
Rezolute Reports First Quarter Fiscal 2024 Results
13 Nov 2023 //
GLOBENEWSWIRE
Rezolute Receives Priority Medicines (PRIME) Eligibility from EMA for RZ358
17 Oct 2023 //
GLOBENEWSWIRE
Rezolute Announces Further Evidence of RZ358™s Efficacy in Hyperinsulinism
11 Oct 2023 //
GLOBENEWSWIRE
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
14 Sep 2023 //
GLOBENEWSWIRE
Rezolute to Participate in Upcoming Investor Conferences in September
06 Sep 2023 //
GLOBENEWSWIRE
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months
27 Jun 2023 //
GLOBENEWSWIRE
Rezolute KOL Event Highlights Significant Unmet Medical Need in DME
23 Mar 2023 //
GLOBENEWSWIRE
Rezolute to Highlight RZ402 PII Clinical Program with Leading Clinical Expert
08 Mar 2023 //
GLOBENEWSWIRE
Rezolute Reports Q2 Fiscal 2023 Results and Highlights Company Progress
10 Feb 2023 //
GLOBENEWSWIRE
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients
15 Dec 2022 //
GLOBENEWSWIRE
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company
09 Nov 2022 //
GLOBENEWSWIRE
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results
15 Sep 2022 //
GLOBENEWSWIRE
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
07 Sep 2022 //
GLOBENEWSWIRE
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
01 Jun 2022 //
GLOBENEWSWIRE
Rezolute Reports Third Quarter Fiscal 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Rezolute, Inc. Announces Closing of Registered Direct Offering
04 May 2022 //
GLOBENEWSWIRE
Rezolute to Host Corporate Update Call on May 4, 2022
04 May 2022 //
GLOBENEWSWIRE
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358
01 May 2022 //
GLOBENEWSWIRE
Rezolute Announces Aggregate $130M Registered Direct Offering
01 May 2022 //
GLOBENEWSWIRE
Rezolute Joins the Rare Disease Company Coalition
29 Mar 2022 //
GLOBENEWSWIRE
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358
23 Mar 2022 //
GLOBENEWSWIRE
Rezolute Reports Q2 Fiscal 2022 Financial Results, Highlights Company Progress
09 Feb 2022 //
GLOBENEWSWIRE
Rezolut Acquires Assets of Westwood Open MRI in Los Angeles
07 Jan 2022 //
PRNEWSWIRE
Rezolute Reports Q1 Fiscal 2022 Financial Results and Highlights Recent Progress
12 Nov 2021 //
GLOBENEWSWIRE
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock
13 Oct 2021 //
GLOBENEWSWIRE
Rezolute slumps on stock and warrants offering
12 Oct 2021 //
SEEKINGALPHA
Rezolute Announces Proposed Public Offering of Common Stock &Pre-Funded Warrants
12 Oct 2021 //
GLOBENEWSWIRE
Rezolute Presents Results from Two-Week Natural History Study
22 Sep 2021 //
GLOBENEWSWIRE
Rezolute EPS beats by $0.03
15 Sep 2021 //
SEEKINGALPHA
Rezolute Initiates Dosing in PIIb Trial of RZ358 for Congenital Hyperinsulinism
09 Sep 2021 //
GLOBENEWSWIRE
Rezolute begins trial of oral drug for diabetic macular edema
12 Aug 2021 //
CLINICAL TRIAL ARENA
Rezolute begins trial of oral drug for diabetic macular edema
12 Aug 2021 //
CLINICAL TRIAL ARENA
Rezolute Added to Russell Microcap® Index
28 Jun 2021 //
GLOBENEWSWIRE
Rezolute Announces Positive RZ402 Study Results
04 May 2021 //
PIPELINE REVIEW
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
22 Mar 2021 //
GLOBENEWSWIRE
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma
12 Jan 2021 //
GLOBENEWSWIRE
Rezolute Announces $41 Million Private Placement with Leading Investment
09 Oct 2020 //
GLOBENEWSWIRE
